Skip to main content

Table 2 Therapeutic data of study patients considered as a whole and by achievement of ID

From: A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis

Therapeutic featuresAll patients (n = 375)Patients who did not achieve ID (n = 146)Patients who achieved ID (n = 229)P#
Median MTX dose, mg/m2 (n = 339)12.8 (11.1–14.5)13.1 (11.6–14.5)12.8 (10.9–14.3)0.2
Route of MTX administration   0.04
 Oral162/367 (44.1)53 (37.3)109 (48.4) 
 Parenteral205/367 (55.9)89 (62.7)116 (51.6) 
Treatment before MTX start
 Intra-articular corticosteroid injections17/372 (4.6)3/143 (2.1)14 (6.1)0.07
 Systemic corticosteroids29/372 (7.8)22/143 (15.4)7 (3.1)< 0.0001
 Other synthetic DMARDs21 (5.6)14/143 (9.8)7 (3.1)0.006
Concomitant therapies during MTX administration
 Intra-articular corticosteroid injections165/374 (44.1)67/145 (46.2)98 (42.8)0.52
 Systemic corticosteroids33/374 (8.8)25/145 (17.2)8 (3.5)< 0.0001
  1. ID inactive disease, MTX methotrexate, DMARDs disease modifying antirheumatic drugs
  2. #P value refers to the comparison between patients who did not achieve or achieved ID
  3. Data are the number (%) unless otherwise indicated